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Background: Adaptation of nanotechnology into materials science has also advanced tissue engineering research.
Tissues are basically composed of nanoscale structures hence making nanofibrous materials closely resemble
natural fibers. Adding a drug release function to such material may further advance their use in tissue repair.
Methods: In the current study, bioabsorbable poly(D,L lactide-co-glycolide)80/20 (PDLGA80/20) was dissolved in a
mixture of acetone/dimethylformamide. Twenty percent of diclofenac sodium was added to the solution. Nanofibers
were manufactured using electrospinning. The morphology of the obtained scaffolds was analyzed by scanning electron
microscopy (SEM). The release of the diclofenac sodium was assessed by UV/Vis spectroscopy. Mouse fibroblasts (MC3T3)
were seeded on the scaffolds, and the cell attachment was evaluated with fluorescent microscopy.
Results: The thickness of electrospun nanomats was about 1 mm. SEM analysis showed that polymeric nanofibers
containing drug particles formed very interconnected porous nanostructures. The average diameter of the
nanofibers was 500 nm. Drug release was measured by means of UV/Vis spectroscopy. After a high start peak, the
release rate decreased considerably during 11 days and lasted about 60 days. During the evaluation of the release
kinetics, a material degradation process was observed. MC3T3 cells attached to the diclofenac sodium-loaded scaffold.
Conclusions: The nanofibrous porous structure made of PDLGA polymer loaded with diclofenac sodium is feasible to
develop, and it may help to improve biomaterial properties for controlled tissue repair and regeneration.
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Recently, electrospinning has been widely studied as a
method for manufacturing biomimetic nanofibrous struc-
tures to be used as scaffolds for cells to grow in and prolif-
erate [1]. Fibers in extracellular matrix (ECM) are in the
nanoscale. Thus, nanofibrous structures are thought to
mimic the fibrous structure of ECM and comprise good
candidates for tissue engineering. Generally, the range of
diameter of electrospun fibers is 5 nm to several microme-
ters. To date, nanofiber-based scaffolds have been manu-
factured from several synthetic and natural polymers and* Correspondence: Elizabeth.Rosado-Balmayor@tum.de
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include poly(ε-caprolactone) (PCL) [2], poly(D,L-lactide)
(PDLLA) [3], poly(glycolide) (PGA) [4], and their blends
such as poly(D,L-lactide-co-glycolide) (PDLGA) [5] and
poly(L-lactide-co-ε-caprolactone) (PDLCLA) [6, 7]. Nat-
ural polymers such as fibrin [8], collagen [9], starch [10],
and chitosan [11] have also been manufactured by electro-
spinning in addition to blends with synthetic polymers
such as collagen-PGA [12] and starch-PCL [13].
More recently, multifunctional electrospun scaffolds
have been developed that contain bioactive substances
[7, 14, 15]. Drug-releasing scaffolds have several advan-
tages besides resembling ECM structure. For example, it
can reduce systemic side effects caused by drugs admin-
istered systematically. Additionally, a therapeutic con-
centration of drugs can be reached locally. Short drugrticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
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scaffolds. For instance, Kim et al. studied the release of
the antibiotic cefoxitin sodium from electrospun PDLGA
nanofibrous scaffolds for 6 days [16]. The authors found
that the maximal dosage of the drug was released during
the first hour of incubation. This can be expected at
least with low molecular weight polymers, which are
usually used for electrospinning. In electrospinning, the
polymer solution should have adequate viscosity to be
able to flow through a needle, in order to form the so-
called “Taylor cone,” and eventually establish nano- or
microfibers onto a collector. However, when long-term
release is desired, these electrospun matrices are
problematic.
The aim of the current study was to develop a bio-
degradable nanofiber-based scaffold with prolonged drug
release. Hence, in the current study, the idea was to use
a high molecular weight (Mw) biodegradable polymer as
a matrix. As a result of the high Mw, the degradation is
expected to be slower (compared to its low Mw equivalent).
Thereby, it prolongs the release of the entrapped drug.
The high molecular weight polymer is, however, a challenge
to an electrospinning process due to the high viscosity of
the polymer solution. In the current study, the selected
matrix polymer was poly(D,L-lactide-co-glycolide)80/20
(PDLGA80/20) with a high inherent viscosity (IV =
5.7 dl/g). PDLGA80/20 is a well-known synthetic bio-
degradable polymer, which has been used in many appli-
cations. The active agent was diclofenac sodium (DS) due
to its long history as a well-known anti-inflammatory
drug. Thus, the DS-releasing scaffold was prepared by
electrospinning, and the drug release, microstructure, and
preliminary cell tests were performed.
Methods
Preparation of the PDLGA80/20 scaffolds loaded with
diclofenac sodium
Bioabsorbable poly(D,L lactic-co-glycolic acid) 80/20
(Purac Biochem, Gorinchem, The Netherlands) was dis-
solved in acetone/dimethylformamide (A/DMF, Sigma-
Aldrich, Espoo, Finland) (ratio 7:1) to create a 6-wt.%
solution. To load the scaffold with the drug, approxi-
mately 20 wt.% of DS (Sigma-Aldrich, Espoo, Finland)
was added to the solution. PDLGA80/20 solution con-
taining DS and plain PDLGA80/20 solutions were
homogenously mixed with a magnetic stirrer. The scaf-
folds were manufactured by electrospinning. The elec-
trospinning apparatus consisted of a glass spinneret
having a metal needle as a capillary, a copper collector
plate covered with aluminum foil, and a voltage source
(Chargemaster BP 50, Simco, Hatfield, PA, USA). The
system was placed in a fume chamber. The voltage
source was attached to both ends so that the needle was
charged positively and the collector plate grounded tozero potential. The distance between the needle tip and
the sample collector was about 10 cm and the applied
voltage was 20 kV. The needle was positioned about 45°
downwards (measured against the surface of the fume
hood) to increase the flow of polymer solution through
the needle. After the electrostatic spinning process, re-
sidual solvent was removed by placing the aluminum foil
into the fume chamber for 24 hours. Thus, allowing the
volatile organic solvents used (i.e., acetone and DMF) to
completely evaporate.
Microstructure
The microstructure of the resulting scaffold was studied
by using scanning electron microscopy (SEM). Samples
were sputtered with gold by using Edwards S150 sputter
coater (Edwards High Vacuum International, Wilmington,
MA, USA) and imaging was done using JEOLT100 (JEOL
Ltd., Tokyo, Japan) with increasing magnitudes up to ×
2000. The average fiber diameter was measured from
SEM micrographs (×2000) by dividing the picture to four
frames and measuring diameters of 20 fibers from each
frame with the aid of Image J 1.33u (Wayne Rasband,
National Institutes of Health, Washington, USA). Based on
these measurements, average fiber and bead diameters
were calculated.
Drug release
Drug release measurements were performed by using a
UV/Vis-spectrophotometer (UNICAM UV 540, Thermo
Spectronic, Cambridge, UK). Five replicate samples were
precisely weighed to be 50 mg and then placed into vials
filled with 5 ml of phosphate buffered solution (PBS,
pH 7.4, Sigma-Aldrich, Espoo, Finland). The vials were
kept in a rotating (100 rpm) incubator (Multitron AJ
118 g, Infors, Bottmingen, Switzerland) at 37 °C. For
every measurement, five parallel samples were collected
at suitable intervals. During the first day, samples were
collected every 6 hours. Subsequently, sample collection
was performed once per day. Based on the results of the
measurements for the earlier points in time, later sam-
ples were collected less frequently (i.e., once per week).
The vials were emptied into test tubes and then refilled
with fresh buffer solution. Concentrations were mea-
sured from samples in the test tubes. PBS pH 7.4 was
used for baseline calibration. The absorbance was then
measured at 276 nm (λmax for DS). The concentration of
DS was calculated using a standard curve with linear re-
gression. The formula for calculation of the concentra-
tion of DS was y = 0.0317× + 0.0091 for concentrations
in the range of 0.5–100 μg/ml and reliability of 0.9999.
After measuring the UV/Vis, the pH value was determined
using a Mettler Toledo MP 225 pH (Mettler-Toledo,
GmbH, Schwerzebbach, Switzerland). The drug-loaded
scaffold was treated with UV light overnight to find
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is known to be UV sensitive [17]. Thus, the release
from UV-treated scaffold was studied in addition to
non-treated scaffold.
Cell culture studies
Cell studies were performed using mouse fibroblasts
(MC3T3). The cells were purchased from European Col-
lection of Cell Cultures (ECACC, Salisbury, UK). Before
seeding the cells to unloaded and DS-loaded scaffolds,
the cells were labeled with the fluorescent dye Vybrant®
DiI (Invitrogen, Carlsbad, California, USA) following the
manufacturer’s instructions. Briefly, 1 × 106 cells were
resuspended in 1-ml serum-free Dulbecco’s modified
Eagle’s medium (DMEM, Sigma-Aldrich, Vienna, Austria).
Subsequently, 5-μl cell-labeling solution was added to
the cell suspension and incubated for 15 min at 37 °C.
Next, labeled cells were washed two times with pre-
warmed serum-free DMEM and were used for cell seeding
experiments.
Electrospun PDLGA80/20 scaffolds were cut into 1 ×
1 cm2 pieces and transferred to individual 24-well tissue
culture plates. On the pre-wetted (i.e., with DMEM cul-
ture medium) electrospun scaffolds, 6 × 103 labeled cells
per cm2 (i.e., per scaffold) were seeded. Cell-seeded scaf-
folds were cultured in DMEM supplemented with 10 %
fetal bovine serum (FBS, Lonza Ltd., Basel, Switzerland)
and 1 % penicillin/streptomycin (P/S, Sigma-Aldrich,
Vienna, Austria) for up to 7 days at 37 °C and 5 % CO2.
One day after cell seeding, fluorescence microscope pic-
tures were taken to evaluate the distribution of the cellsFig. 1 Morphological characterization of the drug-loaded nano-scaffold. Sc
PDLGA80/20 electrospun nano-scaffold a magnification × 500, scale bar = 1
due to the drug encapsulation into the nano-fibers, magnification × 8000, sin the scaffolds. Additionally, 1 and 6 days after seeding,
confocal microscopy (Carl Zeiss LSM 5 PASCAL, Jena,
Germany) was used for examination of attachment of
the cells on the scaffolds. Pictures were analyzed by
using Carl LSM Zeiss Image Browser (Carl Zeiss, Jena,
Germany).Statistical analysis
DS release kinetic values are reported as mean ± stand-
ard deviation (n = 5). Statistical analysis was performed
using GraphPad Prism version 6.00, (GraphPad Software,
La Jolla, CA, USA). Normal distribution of the data was
analyzed by applying the Shapiro-Wilk test. Student’s t
test was used to compare DS release from PDLGA80/20
scaffolds UV-treated with the non-treated ones. All stat-
istical analysis was performed following the recommen-
dations of the software used. Probabilities of p < 0.05
were considered as significant.Results
PDLGA80/20 scaffolds
The thickness of the electrospun scaffolds was about 1 mm.
Under low magnification SEM, polymeric nanofibers
containing drug particles formed a highly interconnected
porous structure (Fig. 1a). Using higher magnifications, it
was seen that the structure also contained beads with dif-
ferent shapes (Fig. 1b, c). The average diameter of nanofi-
bers on the drug-loaded scaffold was 949 ± 500 nm and
that of the beads 17.6 ± 2.7 μm. The fiber diameter of the
unloaded scaffold was 1.0 ± 0.25 μm.anning electron microscopy micrographs of diclofenac sodium-loaded
0 μm; b magnification × 1000, scale bar = 10 μm; c beads formation
cale bar = 1 μm
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The drug release profile showed a high initial peak dur-
ing the first day (burst release). Afterwards, the drug re-
lease rate was decreased considerably during the next
11 days from levels of 20 μg/ml/day to a level of 5 μg/
ml/day. The release period lasted for about 60 days
(Fig. 2). Cumulative release calculations showed that al-
most all loaded DS was released (e.g., 93 % DS was re-
leased after 50 days for the PDLGA80/20 scaffolds not
treated with UV). During the drug release studies, the
size of the scaffolds was notably reduced (based on
visual inspection). Three and a half months after initial
incubation in PBS, the scaffolds vanished completely, in-
dicating an intermediate degradation rate. The UV treat-
ment significantly influenced the release of the drug. A
lower amount of DS was released from the UV-treated
scaffolds when compared to the untreated controls for
each point in time and up to 40 days (Fig. 2). After 4 days
in PBS at 37 °C, levels of released DS were 1.7 ± 0.6 μg/
ml/day for the UV-treated scaffolds in comparison with
9.3 ± 0.8 μg/ml/day for the non-treated ones. Seven days
after incubation in PBS, the effect of the UV treatment
over the DS release was less pronounced. Nevertheless,
this effect was still significant (0.9 ± 0.4 μg/ml/day for
the UV-treated scaffolds in comparison with 4.7 ±
0.2 μg/ml/day for the non-treated ones, p < 0.05). In
terms of cumulative release, this represents 34 % of DS
released after 7 days of incubation for the UV-treated
scaffolds in comparison to 78 % of DS released for the
non-treated ones.Fig. 2 Release profiles of diclofenac sodium from PDLGA80/20 nano-scaffo
the concentration released daily is presented as micrograms per milliliter p
open circles represent the UV-treated ones. On the right scale, the cumulative
non-UV-treated nano-scaffolds, while open squares represent the UV-treated oCell studies
As early as 1 day after seeding, fluorescence microscopy
confirmed the attachment of cells to the PDLGA80/20
scaffolds (Fig. 3). Confocal microscopy revealed cell at-
tachment to both unloaded and DS-loaded scaffolds on
day 1 and day 6 (Fig. 4). Interestingly, the cells have
preference for the unloaded scaffolds, as more cells are
observed per microscopic field in them (Fig. 3).
Discussion
During the past decade, nanofibrous structures have in-
tensively been studied as scaffold materials for tissue en-
gineering [18]. One of the most popular techniques to
produce these structures is electrospinning. Diverse fi-
brous structures can be manufactured by changing single
parameters during the electrospinning process (e.g., volt-
age, needle diameter, and pressure). In our study, previ-
ously optimized electrospinning parameters were used to
produce the PDLGA80/20 and DS-loaded PDLGA80/20
scaffolds [7]. In addition, material properties such as poly-
mer molecular weight, solubility, volatility, and dielectric
constant of the solvent together with the polymer concen-
tration are of relevance for a successful electrospinning
[19]. The selected polymer for our study, PDLGA80/20, as
many synthetic polymers is soluble only in organic sol-
vents. It dissolves in chloroform and also in acetone at
low concentrations. Such solvents are often toxic for the
cells and might also damage added active agents. On the
other hand, the chosen drug, DS is stable and highly
soluble in water, ethanol, DMF, and dimethyl sulfoxidelds. The release study was performed in PBS at 37 °C. On the left scale,
er day. The closed circles represent non-UV-treated nano-scaffolds, while
release is presented as percentage. Similarly, the closed squares represent
nes
Fig. 3 Mouse fibroblasts cells seeded onto the nano-scaffolds. Fluorescence microscopy images of mouse fibroblasts cells (MC3T3) 1 day after
seeding onto the PDLGA80/20 scaffolds a diclofenac sodium-loaded scaffold, b unloaded scaffolds. Cells were previously labeled with Vybrant Dil
(red fluorescence)
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Acetone is a highly volatile solvent, commonly used as ex-
cipient in many pharmaceutical formulations [20]. Due to
its high volatility, the solvent can be removed from the scaf-
folds by allowing overnight air-dry or vacuum-dry. Thus,
the solvent used in the current study was chosen to be acet-
one. When PDLGA80/20 was dissolved in acetone, itFig. 4 Cell attachment to the nano-scaffold. Confocal microscopy images rev
sodium-loaded PDLGA80/20 scaffolds. The cells were labeled with Vybrant Di
after seeding while c and d resemble the cells attached to the scaffold 6 daysresulted in an electrospraying rather than an electrospin-
ning process. Subsequently, a mixture of acetone and DMF
was used. As a result, the formation of the jet and Taylor
cone previously described by Kim et al. [16] was enhanced.
Special attention was given to use the minimal amount of
DMF indispensable needed for the electrospinning process.
This was based on the known toxicity associated to DMF.ealed cell attachment of mouse fibroblasts cells (MC3T3) to the diclofenac
l fluorochrome immediately before seeding. a and b correspond to 1 day
after seeding. a and c show the scaffold from the side
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nanomats were allowed to air-dry for 24 hours to remove
solvent remnants.
Conductivity of polymer/drug solution was not mea-
sured. However, DMF has a high dielectric constant.
Thus, it can be expected that conductivity of the poly-
mer solution may have increased after addition of DMF.
Adding ions to the polymer solution, e.g., in the form
of drugs, can enhance the process of electrospinning
[21]. Indeed, the presence of DS enhanced the scaffold
fabrication in our study. No differences between fiber di-
ameters of unloaded and DS-loaded scaffolds were ob-
served. Both scaffolds were prepared with the same
solute concentration and under the same processing pa-
rameters. The examination of the microstructure re-
vealed nanofibrous structures and beads. Fiber diameters
varied considerably in both scaffold types, as indicated
by a high standard deviation. The shape of the beads
was irregular, and most of them were large when com-
pared to the nanofibers. Another important property to
be considered is the polymer molecular weight. Most
ester-based biodegradable electrospun scaffolds have
been made using low molecular weight (60 000–80
000 g/mol) polymers [16, 22] since they are more suit-
able for processing. However, low molecular weight
ester-based biodegradable polymers degrade and release
encapsulated agents faster than polyesters with high mo-
lecular weight. The high inherent molecular weight of
the PDLGA80/20 polymer was thought to prolong the
release period since the degradation is slower compared
to low molecular weight PDLGA.
The main problem in prolonging drug release from
nanofibrous structures lies in the nanoscale itself and in
the biodegradation properties of the material. On the
one hand, nanostructures are characterized by a large
surface-area-to-volume ratio that is prone to hydrolysis.
Viitanen et al. observed a faster release on nanostruc-
tures when compared to bulkier constructs that were
manufactured using the same polymer and drug by, for
instance, melt extrusion [23]. On the other hand, fast de-
grading biodegradable polymers release the encapsulated
agent quite quickly as the material degrades. In our
study, one way to attempt to control the release of DS
was to use the high molecular weight PDLGA80/20
polymer. The high molecular weight is expected to de-
crease the degradation rate of the scaffold and thus to
control the release of encapsulated DS. In addition, DS
is a hydrophilic compound. Knowing that PDLGA80/20
is hydrophobic, the release rate could also be decreased
since the diffusion of DS to the surroundings would be
compromised.
In the current study, a concentration of 0.12 μg/ml
was considered to be the lowest therapeutic concentra-
tion of DS. It is reported to be the lowest level insynovial fluid after 12 hours of oral administration of
75 mg DS which has a therapeutic effect [24]. The re-
lease rate of DS from the PDLGA80/20 scaffolds was
not constant. A burst release was observed during the
first day in vitro, decreasing thereafter to levels of lower
than 1 μg/ml after 60 days. This might already be advan-
tageous when controlling the inflammatory reaction
after implantation. The matrix polymer also has an effect
on the drug-release rate. Nikkola et al. [7] reported that
the release period of drug-loaded nanofibrous poly(lac-
tide-co-ε-caprolactone (PCL95/5) was about 90 days.
PCL95/5 (molecular weight 81,500 g/mol) is a slowly de-
grading polymer, and thus the total release time is long.
Kim et al. [16] reported drug release from PDLGA
within few hours. The molecular weight in this case was
75,000 g/mol.
Considering nanofiber-based scaffolds as constructs
for tissue engineering, multiple studies with cells have
been made [4, 13, 18]. Cell studies of loaded scaffolds
have mainly concentrated on DNA-loaded scaffolds for
tissue engineering [25] and treatment of cancerous cells
[26]. A few studies like the one by Chua et al. [27] re-
ported the development of 3-methylcholanthrene-loaded
dual functional scaffold seeded with hepatocytes. In the
current study, the objective of cell culture tests was to
evaluate the effect of DS release to the cells. It was no-
ticed that after 1 day of culture, mouse fibroblasts at-
tached rather to an unloaded PDLGA80/20 scaffold than
to a DS-loaded scaffold. This could be explained consid-
ering both the porosity of the scaffolds and the effect of
DS on the cells. DS-loaded scaffolds were characterized
by denser structures with fibers closer to each other as
seen in the SEM images. Thus, it can be expected that
the cells may be unable to penetrate to the interior of
the scaffolds. In addition, DS is known to reduce prolif-
eration of fibroblast in vitro. Sun et al. reported that DS
among other non-steroidal anti-inflammatory drugs sig-
nificantly inhibited human Tenon’s capsule fibroblast
growth in vitro [28]. Six days after seeding, cells attached
to the DS-loaded scaffolds. An increased number of cells
were observed compared to the first day after seeding.
Over 70 % of entrapped DS was released during the first
6 days. Regarding sterilization methods for the scaffold,
UV light has often been used due to its easy accessibility
and low costs. In our study, UV light showed to have an
effect on the release of DS. The retardation on the re-
lease of the drug could be due to a partial degradation of
the DS. Hassanzadeh-Khayyat et al. reported that UV ir-
radiation might partially affect the activity of DS. As a
consequence, the absorbance at 276 nm (λmax for DS)
diminished or no peak at all was observed [29]. In addition,
a change in coloration (to yellowish) of the DS-loaded ma-
terials after UV exposure associated with the formation of
degradation products has been described [29]. This was not
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point of the study. Other sterilization methods, such as
gamma irradiation could be of benefit for DS-loaded
constructs. Further cell culture studies as well as in vivo
studies need to be performed for the developed DS-loaded
PDLGA80/20 scaffold. Other therapeutic molecules, such
as growth factors, could be encapsulated.
In previous studies, we have reported the fabrication
of electrospun nanofiber-based scaffold using PCL95/5
[7], poly(maleic anhydride-alt-2-methoxyethyl vinyl ether)
(PAM14) [30], and several poly(3-hydroxybutyrate-co-3-
hydroxyvalerate) (PHBV) blends [31]. Both PCL95/5 and
PAM14 were loaded with DS during the electrospinning
process. In this study, we report the fabrication of
PDLGA80/20 electrospun nanofiber-based scaffold loaded
with DS. The present study applied previously optimized
experimental conditions to fabricate a new type of electro-
spun nanofiber-based scaffold. When comparing the three
different types of scaffolds loaded with DS, the fastest re-
lease of DS was obtained with PAM14. Both PCL95/5 and
PDLGA80/20 provided a prolonged released of the DS.
PCL95/5 will degrade slower than PDLGA80/20. Thus,
PCL95/5 could be used in cases were long-term scaffold
support is needed for the cells.
Conclusions
Electrospinning proved to be a feasible technique for the
production of DS-loaded PDLGA80/20 scaffolds. The re-
lease of DS was prolonged in vitro when compared to
other drug-loaded PDLGA scaffolds, by using high mo-
lecular weight PDLGA. The DS-loaded scaffolds had small
pore sizes. This may result in a limited cell colonization of
the entire scaffold. Nevertheless, the porosity could be im-
proved by adjusting the processing parameters. The DS
did not present any structural changes, thus suggesting
electrospinning is a suitable process for manufacturing
DS-loaded scaffolds. However, in this study, we did not
perform a bioactivity test on the released DS. This meas-
urement should be considered in further studies with this
system to prove that the electrospinning process did not
compromise the anti-inflammatory activity of the en-
trapped drug. Nevertheless, we feel that we could show a
successful fabrication of DS-loaded nanofiber-based scaf-
folds that may have a role in tissue engineering. DS is a
commonly used anti-inflammatory drug. Tissue damage
may appear, for example, as result of biomaterial implant-
ation to a bone defect where the surrounding tissue may
present an inflammatory process. Here, our DS-loaded
scaffolds could be of good applicability. An example of an
in vivo study for our construct may be to use the loaded
electrospun scaffolds to cover the outside part of a bone
defect. Thus, the loaded nanomats could mimic the
function of the periosteum providing enclosure of the
bone defect and controlling the associated inflammation.Abbreviations
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